Capricor Therapeutics Inc (CAPR) Stock News

Capricor Therapeutics faces a securities class action lawsuit alleging materially misleading statements regarding clinical trial data for its lead drug candidate deramiocel. The company's stock crashed 64% after FDA briefing documents revealed undisclosed modifications to the statistical analysis plan for the HOPE-3 study, which failed to meet pre-specified primary and secondary efficacy endpoints. Investors with losses between December 17, 2025, and July 26, 2026, have until September 28, 2026, to seek lead plaintiff status.

Faruqi & Faruqi, LLP is investigating securities fraud claims against Capricor Therapeutics for allegedly making misleading statements about its Deramiocel drug's regulatory prospects. The company allegedly failed to disclose changes to its statistical analysis plan and lack of FDA agreement before resubmitting the Biologics License Application. Capricor's stock plummeted 64% on July 27, 2026, after the FDA released unfavorable briefing documents, and fell an additional 36% on July 30, 2026, following an AdCom panel's 9-3 vote against the drug's efficacy. Investors who purchased securities between December 17, 2025 and July 26, 2026 may be eligible to participate in the class action lawsuit, with a September 28, 2026 deadline to seek lead plaintiff status.

Schall, Brown & Schwartz LLP announced a class action securities fraud lawsuit against Capricor Therapeutics for making false and misleading statements regarding its Deramiocel drug candidate. The company allegedly changed its statistical analysis plan without FDA approval before resubmitting its Biologics License Application, creating significant risk of non-approval. The class period spans December 17, 2025 to July 26, 2026, with a September 28, 2026 deadline for investors to participate.

Hagens Berman notifies Capricor Therapeutics investors of a September 28, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges the company made materially false statements about clinical trial data for its drug deramiocel, failing to disclose undisclosed changes to the statistical analysis plan. After the FDA revealed the HOPE-3 study did not meet pre-specified endpoints, Capricor's stock crashed 64% on July 27, 2026.

Law firm Kirby McInerney LLP is alerting investors about pending securities fraud class action lawsuits against Capricor Therapeutics, Rackspace Technology, and Bloom Energy. The primary focus is on Capricor, which faces allegations of making false statements regarding changes to its statistical analysis plan for the Deramiocel drug candidate without FDA approval. The FDA subsequently rejected the drug, causing Capricor's stock to plummet 64% on July 27, 2026, and an additional 36% on July 30, 2026. The lead plaintiff deadline is September 28, 2026.

A class action lawsuit has been filed against Capricor Therapeutics for allegedly making false statements about its Deramiocel cell therapy between December 2025 and July 2026. The FDA's briefing documents criticized the company's statistical analysis methods, and an advisory panel voted 9-3 against the therapy's efficacy, causing the stock to plummet 62% on July 27, 2026. Investors who purchased shares during the class period are urged to file claims by September 28, 2026.

Rosen Law Firm reminds investors in Capricor Therapeutics, Inc. (CAPR) of the September 28, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Capricor made false statements regarding changes to statistical analysis plans for its Deramiocel treatment without FDA approval, creating substantial risk of regulatory rejection and misleading investors about the company's prospects.

Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary case involves Capricor Therapeutics, which allegedly made false statements about its Deramiocel cell therapy by failing to disclose changes to statistical analysis plans and lack of FDA agreement before resubmitting its Biologics License Application. The lead plaintiff deadline is September 28, 2026. Additional lawsuits involve Innventure, Inc. and Planet Fitness, Inc.

Rosen Law Firm alerts investors in Capricor Therapeutics (CAPR) who purchased securities between December 17, 2025 and July 26, 2026 of an important September 28, 2026 deadline to join a securities class action. The lawsuit alleges that Capricor made materially false statements regarding changes to its statistical analysis plan for Deramiocel without FDA agreement, creating significant regulatory approval risks that were not properly disclosed to investors.

Capricor Therapeutics faces a securities fraud class action lawsuit alleging the company made false statements about its lead product Deramiocel and misrepresented clinical data integrity in its FDA Biologics License Application. The lawsuit was triggered by a 64.5% stock drop on July 27, 2026, following FDA briefing documents that raised concerns about post-hoc changes to the statistical analysis plan. Investors have until September 28, 2026 to request lead plaintiff status.

Pomerantz LLP has filed a class action lawsuit against Capricor Therapeutics for alleged securities fraud related to its Deramiocel BLA submission to the FDA. The FDA's briefing documents revealed that Capricor altered its statistical analysis plan one day before data unblinding without FDA approval, leading the FDA to deem the analyses as 'post-hoc and exploratory.' Following the FDA's negative assessment on July 27, 2026, Capricor's stock plummeted 64%, and an advisory committee voted 9-3 against the drug's efficacy on July 30, 2026, causing an additional 36% stock decline.

Dimensional Fund Advisors Ltd. has disclosed a 3.36% stake in Capricorn Energy PLC, comprising 2,402,085 ordinary shares as of September 7, 2026. The disclosure includes a sale of 2,247 shares at 3.84 GBP per unit. Dimensional clarifies it does not have discretion over voting rights for 7,767 of the shares held.

Rosen Law Firm announces securities class action lawsuits against multiple companies, including Capricor Therapeutics, for allegedly making materially false statements. Capricor is accused of failing to disclose changes to statistical analysis plans for its Deramiocel cell therapy and FDA concerns regarding regulatory approval for Duchenne muscular dystrophy treatment. Investors with losses exceeding $100K are encouraged to join the class action before the September 28, 2026 deadline.

Capricor Therapeutics (CAPR) shares surged 144% over the past month following positive phase III HOPE-3 data showing a 54% reduction in upper-limb function decline for its deramiocel cell therapy in Duchenne muscular dystrophy. After an initial FDA rejection, the company refined its indication to focus on upper-limb function, and the FDA accepted the resubmission with a new PDUFA date of November 22, 2026. The stock rally reflects renewed investor optimism despite substantial regulatory risk.

Dimensional Fund Advisors Ltd. has disclosed a 3.37% interest in Capricorn Energy PLC, comprising 2,404,332 ordinary shares as of September 4, 2026. The disclosure was made on September 7, 2026, following a sale of 4,476 shares at 3.8290 GBP per unit. Dimensional clarifies it does not have discretion over 7,767 of the shares included in this position.

Rosen Law Firm reminds investors who purchased Capricor Therapeutics securities between December 17, 2025 and July 26, 2026 of the September 28, 2026 deadline to become lead plaintiffs in a securities class action. The lawsuit alleges the company made false statements regarding modifications to statistical analysis plans for its Deramiocel cell therapy and FDA approval risks for treating Duchenne muscular dystrophy.

Rosen Law Firm is reminding investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) who purchased securities between December 17, 2025 and July 26, 2026 of the September 28, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Capricor made materially false statements regarding changes to its statistical analysis plan for Deramiocel without FDA approval, creating significant regulatory risk for the cell therapy's approval for treating Duchenne muscular dystrophy.

Schall, Brown & Schwartz LLP announced a class action securities fraud lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) for allegedly making false and misleading statements regarding its Deramiocel drug candidate. The company allegedly changed its statistical analysis plan without FDA approval before resubmitting its Biologics License Application, creating significant risk of FDA rejection. The class period spans December 17, 2025 to July 26, 2026, with a September 28, 2026 deadline for investors to participate.

Capricor Therapeutics faces a securities class action lawsuit alleging material misstatements regarding clinical trial data for its lead drug deramiocel. The FDA extended the review period for the drug's Biologics License Application to November 2026 after revealing the company made undisclosed modifications to its statistical analysis plan. The stock crashed 64% on July 27, 2026, when FDA briefing documents revealed the HOPE-3 study failed to meet pre-specified primary endpoints. Investors who purchased shares between December 17, 2025, and July 26, 2026, have until September 28, 2026, to seek lead plaintiff status.

Rosen Law Firm announces class action securities lawsuits against Capricor Therapeutics (CAPR) and Rackspace Technology (RXT). The CAPR lawsuit alleges the company made false statements regarding changes to statistical analysis plans for its Deramiocel treatment without FDA approval, creating regulatory risks. Investors who suffered losses exceeding $100,000 during the specified periods are encouraged to join the lawsuits before the September 28, 2026 deadline.

A securities fraud class action lawsuit has been filed against Capricor Therapeutics (CAPR) for allegedly making material misstatements regarding its lead product Deramiocel's statistical analysis plan and FDA compliance. The FDA revealed that Capricor made undisclosed changes to the pre-specified statistical analysis plan without prior FDA agreement, leading to FDA disagreement with the methodology. Following the FDA's unfavorable briefing documents on July 27, 2026, Capricor's stock price fell 64%. Investors who purchased CAPR securities between December 17, 2025 and July 26, 2026 can seek lead plaintiff status by September 28, 2026.

A securities class action lawsuit has been filed against Capricor Therapeutics for allegedly making materially false statements regarding its Deramiocel cell therapy. The lawsuit claims the company made undisclosed changes to statistical analysis plans for clinical data and failed to obtain FDA agreement before resubmitting the Biologics License Application, creating substantial regulatory approval risks. Investors who purchased securities between December 17, 2025 and July 26, 2026 may be eligible for compensation, with a lead plaintiff deadline of September 28, 2026.

Kaplan Fox & Kilsheimer LLP has filed class action lawsuits against Capricor Therapeutics, Pentair plc, and Bloom Energy Corporation on behalf of investors who suffered losses. The primary case involves Capricor, where the FDA released briefing documents revealing that the company made undisclosed changes to its statistical analysis plan for a drug application, resulting in a 64% stock price drop on July 27, 2026.

Capricor Therapeutics faces a class action securities fraud lawsuit after the FDA criticized the company's statistical analysis methods for its Deramiocel cell therapy trial. The FDA's briefing documents questioned the scientific justification for data conversion methods and concluded the benefit-risk assessment was unfavorable. Following the FDA's concerns and an advisory committee's 9-3 vote against efficacy, Capricor's stock plummeted 62% on July 27, 2026. Investors who purchased shares between December 17, 2025 and July 26, 2026 can file lead plaintiff motions by September 28, 2026.

Capricor Therapeutics reported Q2 2026 results with a net loss of $40.7 million ($0.70 per share) and cash reserves of $237.9 million. The company faced a significant setback when the FDA Advisory Committee voted 3-9 against approving Deramiocel for cardiomyopathy in DMD patients. However, management plans to submit a BLA amendment focusing on upper limb skeletal muscle function, supported by positive HOPE-3 primary endpoint data showing statistically significant slowing of disease progression (p=0.029). The company is scaling manufacturing capacity and pursuing arbitration with NS Pharma over distribution agreement disputes.

A class action lawsuit has been filed against Capricor Therapeutics for allegedly making false statements regarding changes to its statistical analysis plan for the Deramiocel drug candidate without FDA approval. The FDA's briefing documents revealed concerns about the integrity of the clinical data analysis, leading to a 64% stock price decline on July 27, 2026, followed by a 36% decline after an advisory committee voted against the drug's efficacy on July 29, 2026.

A class action lawsuit has been filed against Capricor Therapeutics (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025 and July 26, 2026. The lawsuit alleges that Capricor made materially false statements regarding changes to its statistical analysis plan for Deramiocel without FDA agreement, creating significant regulatory approval risks. Investors who purchased during this period may be entitled to compensation.

Rosen Law Firm has filed a class action lawsuit against Capricor Therapeutics (CAPR) on behalf of investors who purchased securities between December 17, 2025 and July 26, 2026. The lawsuit alleges that Capricor made materially false statements regarding changes to its statistical analysis plan for Deramiocel without FDA approval, creating significant regulatory risk for the cell therapy's approval for treating Duchenne muscular dystrophy. Investors must move the court by September 28, 2026 to serve as lead plaintiff.

A securities class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025 and July 6, 2026. The lawsuit alleges the company made materially false and misleading statements regarding business operations, growth prospects, and financial stability, causing securities to trade at artificially inflated prices. Investors who suffered losses are encouraged to contact the law firm or submit claims by September 28, 2026 to potentially serve as lead plaintiff.

A class action lawsuit has been filed against Capricor Therapeutics for allegedly making false statements about its lead drug candidate Deramiocel. The FDA rejected the drug application after discovering undisclosed changes to the statistical analysis plan, causing Capricor's stock to plummet 64% on July 27, 2026, and an additional 36% on July 29, 2026, following an advisory committee vote against the drug's efficacy.